US FDA approves use of Bristol s cell therapy for rare blood cancer yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Insmed said on Tuesday its
experimental drug to treat a type of chronic lung disease met
the main goal in a late-stage study, sending shares up nearly
three times in premarket trading.
(Reporting by.
Healthcare payments company Waystar
said on Tuesday it was targeting a valuation of up to $3.83
billion in its initial public offering in the United States. Louisville, Kentucky-based.
(Reuters) -Healthcare payments company Waystar said on Tuesday it was targeting a valuation of up to $3.83 billion in its initial public offering in the United States, joining a clutch of companies looking to tap into improving investor appetite for ne.
Insmed said its drug candidate for a chronic lung disease helped significantly reduce the frequency of respiratory symptoms such as chronic cough in a late-stage study,.